Skip to main content

Table 3 Subgroup analysis of the recurrence rate in patients treated with DAs and surgery treatment

From: Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis

  DAs Surgery
Pooled result Number of studies Number of patients Pooled result Number of studies Number of patients
Total 0.57 (0.48, 0.67) 19 835 0.19 (0.15, 0.24) 36 1215
Microprolactinoma 0.63 (0.49, 0.78) 7 380 0.10 (0.04, 0.17) 10 206
Macroprolactinoma 0.60 (0.39, 0.81) 6 226 0.34 (0.11, 0.56) 8 112
Giant prolactinoma NAa NAa NAa NAa NAa NAa
1980–1989 0.79 1 24 0.28 (0.16, 0.39) 13 374
1990–1999 0.81 (0.58, 1.04) 2 31 0.17 (− 0.01, 0.35) 3 149
2000–2009 0.51 (0.37, 0.65) 4 329 0.15 (0.09, 0.21) 6 278
2010–2019 0.54 (0.41, 0.67) 12 451 0.15 (0.09, 0.20) 14 414
Bromocriptine 0.86 (0.73, 0.98) 2 36 NAb NAb NAb
Cabergoline 0.55 (0.39, 0.70) 6 336 NAb NAb NAb
Microscopic surgery NAb NAb NAb 0.13 (0.05, 0.21) 5 177
Endoscopic surgery NAb NAb NAb 0.13 (0.05, 0.21) 3 75
  1. Das dopamine agonists, NAa not applicable, because the data was not provided by included studies, NAb not applicable, because the data was not discussed or calculated in the meta-analysis